University of Wisconsin Carbone Cancer Center | Strategic Alliance Partners

Institutional Perspectives in Cancer: Multiple Myeloma - Chaired by Douglas Sborov, MD, MS

Electronic health record systems’ design, usability, and interoperability issues can hinder integration and use.

A new focus of research has reconsidered the mechanisms in regulating transcription as a novel target for advanced pancreatic ductal adenocarcinoma.

Highly effective tools, such as immunotherapeutic agents, have emerged for the treatment of patients with a wide range of malignancies.

Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.

At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.

Stephen L. Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer.

Utilizing a multidisciplinary approach to care is critical in the field of ovarian cancer with the substantial advancements that have been made with systemic chemotherapeutic regimens, PARP inhibitors, maintenance therapy, and surgical interventions.

Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

The debate continues as to how to define oligometastatic disease and whether it represents a unique stage between limited-stage and widely metastatic disease.

Nataliya V. Uboha, MD, PhD, zeros in on the developments with ADCs and monoclonal antibodies in gastric cancer and recent changes in pancreatic cancer as key takeaways from the event.

Monica A. Patel, MD, discusses factors that determine whether a patient with hepatocellular carcinoma is a good candidate to receive a combination of atezolizumab and bevacizumab.

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.

Natalie S. Callander, MD, discusses the intriguing approaches in both the frontline and relapsed/refractory settings, including trials with antibody-drug conjugates.

Timothy M. Schmidt, MD, discusses the safety and efficacy of teclistamab in patients with multiple myeloma.

Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.

Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of multiple myeloma.

Unprecedented treatment advances have been made during the last decade for patients with advanced melanoma.

Kari B. Wisinski, MD, discusses the evolving roles of immunotherapy, ADCs, and PARP inhibitors in triple negative breast cancer.

Parameswaran Hari, MD, MRCP, discusses key data that has read out in relapsed/refractory multiple myeloma, exciting agents generating excitement, and the role of minimal residual disease.

Elisavet Paplomata, MD, discusses the role of tucatinib ​in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.

In our exclusive interview, O’Regan discusses the protocols the University of Wisconsin Carbone Cancer Center has put into place in light of COVID-19, the rise of telemedicine, best practices for in-person visits in the clinic, and the importance of maintaining well visits throughout the pandemic.